A recent real-world retrospective study conducted across six French cancer centers has shed light on the efficacy and safety of neoadjuvant immune checkpoint inhibitors (ICIs) in patients with nonmetastatic colon cancer harboring mismatch repair-deficient (dMMR)/microsatellite instability (MSI) status. The study, focusing on agents like pembrolizumab, nivolumab, and ipilimumab, revealed a notable pathologic response rate, albeit lower than what had been observed in controlled clinical trials. This emphasizes the importance of understanding the differences in outcomes between selected patient cohorts in trials and real-world patient populations.
The study cohort comprised 32 eligible patients treated between 2019 and 2024, with pembrolizumab being administered to 69% and a combination of nivolumab and ipilimumab to 31% of the participants. Pathological response served as the primary endpoint, while secondary endpoints included tolerability, toxicity, recurrence-free survival, and overall survival. The results indicated a significant rate of pathologic response, with the combination therapy arm showing a higher complete pathologic response compared to the monotherapy arm.
In terms of adverse events, the study reported that 19% of patients experienced grade 1/2 adverse events, while 19% experienced grade 3 or higher adverse events. Notably, the toxicity profile was higher in the combination therapy arm compared to the monotherapy arm, resulting in treatment discontinuation for three patients due to toxicity concerns. This underscores the importance of carefully monitoring and managing adverse events associated with neoadjuvant ICI regimens.
The study highlighted the importance of real-world evidence in assessing the efficacy and safety of neoadjuvant ICIs in patients with dMMR/MSI nonmetastatic colon cancer. The findings suggested that combination therapy might offer superior outcomes compared to monotherapy, indicating the need for further research to optimize treatment strategies. Additionally, the study emphasized the necessity of standardizing patient selection criteria and treatment protocols to enhance the efficacy and tolerability of neoadjuvant immunotherapy in this patient population.
Key Takeaways:
– Real-world evidence supports the use of neoadjuvant immunotherapy in nonmetastatic colon cancer with dMMR/MSI status, albeit with lower response rates than in clinical trials.
– Combination therapy may offer better outcomes than monotherapy in terms of pathologic response.
– Adverse events, particularly grade 3 or higher toxicities, need careful monitoring and management to ensure treatment continuation and patient safety.
– Standardizing patient selection criteria and treatment protocols is crucial to optimize the effectiveness and safety of neoadjuvant immunotherapy in this patient population.
Tags: immunotherapy
Read more on targetedonc.com